Current Report Filing (8-k)
November 16 2020 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event
reported): November 16, 2020
iBio,
Inc.
(Exact name of registrant as specified
in charter)
Delaware
(State or other jurisdiction of incorporation)
001-35023
|
26-2797813
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
8800 HSC Parkway
Bryan, Texas 77807
(Address of principal executive offices
and zip code)
(979) 446-0027
(Registrant’s telephone number
including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class
|
Trading Symbol(s)
|
Name of each exchange
on which registered
|
Common Stock, $0.001
par value per share
|
IBIO
|
NYSE American
|
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 16, 2020, iBio, Inc. (the
“Company”) issued a press release announcing its financial results for the quarter ended September 30, 2020. A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and
in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed incorporated by reference
into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit is furnished with this Current Report
on Form 8-K.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IBIO
INC.
|
|
|
Date: November 16, 2020
|
By:
|
/s/ Thomas F. Isett
|
|
|
|
Name:
|
Thomas F. Isett
|
|
|
|
Title:
|
Chairman and Chief Executive Officer
|
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024